Blood-based Biomarkers for Early Disease Detection in Cardiac Amyloidosis


About this study

The purpose of this study is to characterize proteomic signatures using MS and annotate respective biological function. Also, to evaluate immunosignatures using a 15-mer PM to detect aAb binding against immune epitopes. and to characterize spectral signatures using polarized imaging microscopy.


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Subjects > 24 years of age will be consented and enrolled at Mayo Clinic into one of five groups:
    • Healthy controls (HC);
    • Heart Failure (HF) unrelated to amyloidosis of any form (HF);
    • HF with a diagnosis of ATTRwt;
    • HF with a diagnosis of ATTRh; and
    • HF with a diagnosis of light chain amyloidosis (AL). 

Exclusion Criteria:

  • < 24 years of age. 

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 7/21/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Julie Rosenthal, M.D.

Open for enrollment

Contact information:

Clinical Studies Unit

(904) 953-2255

More information


Publications are currently not available